Can adding radiation therapy to the usually prescribed immune therapy increase the time without your renal cell cancer getting worse or requiring surgery?

NRG ONCOLOGY

Advancing Research. Improving Lives.™

Visit the patient webpage for this study:

Watch our patient study overview video:

SCAN ME

ABOUT THE TRIAL

NRG-GU012 is a clinical study for people with renal cell cancer that has spread beyond the kidneys, also known as metastatic renal cell cancer. This trial is specifically for patients who are not planning on receiving surgery for their disease, or for patients not recommended to receive surgery at the time of their diagnosis.

Researchers are performing this study to see if adding radiation therapy to your kidney tumor to the usual treatment of immune therapy can help stabilize your cancer or possibly cause it to shrink. The immune therapy normally prescribed for metastatic renal cell cancer consists of either two immune therapy drugs or immune therapy plus a targeted therapy drug called a VEGF inhibitor. Researchers will randomly assign patients to receive either the immune therapy treatment alone or to receive the immune therapy combined with the radiation therapy.

This study will help the study doctors find out if this different approach is better, the same, or worse than the usual approach. To decide if it is better, the study doctors will be looking to see if the study approach increases the time without cancer progressing by 6 months or more compared to the usual approach.

ABOUT NRG ONCOLOGY

As one of the five research groups in the National Cancer Institute's (NCI) National Clinical Trials Network (NCTN), NRG Oncology carries out clinical trials on sex-specific malignancies, including gynecologic, breast, and prostate cancers, and on localized or locally advanced cancers of all types. NRG Oncology's extensive research organization includes investigators, medical oncologists, radiation oncologists, surgeons, physicists, pathologists, and statisticians. The NRG Oncology includes more than 1,300 research sites worldwide, primarily in the United States and Canada. NRG Oncology is a non-profit research organization, funded mainly through grants from the NCI. To contact NRG Oncology, call 267-519-6630 or email info@nrgoncology.org

VERSION DATE: 2/24/2025

Frequently Asked Questions

What is a clinical trial?
Clinical trials are research studies that look to find better ways to prevent, diagnose, or treat disease.

Who can join this study?
People who are 18 years or older with renal cell cancer that has spread beyond your kidney and surgery is not currently recommended OR you have chosen not to have surgery.

Am I required to be in this study?
No. Taking part in this study is voluntary. You are free to choose to participate or not to participate. If you choose to participate in this study, you are able to leave the study at any time. If you decide not to take part in this study, your doctor will discuss other treatment options with you.

What are the possible treatments?
If you decide to take part in the study, you will be randomly assigned to one of two possible study groups. Patients in Study Group 1 will receive the usual immune therapy which consists of either 2 immune therapy drugs OR immune therapy plus a targeted therapy drug called a VEGF inhibitor. Patients in Study Group 2 will receive the same immune therapy as in Group 1 with the additional radiation therapy to your kidney tumor. In this trial, there is a higher chance that you will be assigned to Group 2 and a lower chance that you will be assigned to Group 1.

How long will I be in this study?
Patients in both Study Groups will receive the usual immune therapy until it is no longer working to control your cancer. Patients in Study Group 2 receiving the additional radiation treatment will be given radiation on 3 different days during week 1-3 of starting immune therapy. If your tumor is smaller after 2 years of treatment, your doctor will discuss potentially stopping treatment with you.

After your treatment is stopped, your doctor and study team will watch you for side effects. They will monitor you every 6 months for 5 years after treatment and then annually for 3 years.

Are there side effects?
There may be some. The most common side effects of radiation treatment to the kidney include: hair loss in the abdominal area or back, tiredness, diarrhea, nausea, and rarely injury to the intestines or healthy kidney. The most common side effects of immune therapy drugs include: anemia, diarrhea, nausea, vomiting, chills and fever, flu-like symptoms, infection, reaction during or following drug infusions, bruising and bleeding, loss of appetite, cough, dry skin, rash, itching, or acne. Your doctor will review all potential side effects with you.

MORE INFORMATION

Visit the National Cancer Institute website at https://www.cancer.gov for more information about studies or general information about cancer.
You may also call: 1-(800)-4-CANCER (1-800-422-6237).